Relmada Therapeutics (RLMD) Non Operating Interest Expenses (2012 - 2013)
Relmada Therapeutics' (RLMD) quarterly Non Operating Interest Expenses came in at $723.0 in Q1 2013, up 133.98% on a QoQ basis from $309.0 in Q4 2012.
Relmada Therapeutics (RLMD) Non Operating Interest Expenses (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Non Operating Interest Expenses data on file, last reported at $723.0 in Q1 2013.
- On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $723.0 in Q1 2013; TTM through Aug 2013 was $1032.0, a N/A change from a year earlier, with the FY2013 full-year figure at $1032.0, down 78.17% from the prior year.
- Non Operating Interest Expenses for Q1 2013 stood at $723.0, up from $309.0 in the prior quarter.
- Over the last five years, Non Operating Interest Expenses for RLMD reached as high as $2589.0 in Q2 2012 and fell as low as $309.0 in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -220,921.81 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Relmada Therapeutics | 205.29 Mn | 205.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2013 | 723.00 |
| Nov 30, 2012 | 309.00 |
| Aug 31, 2012 | 1,048.00 |
| May 31, 2012 | 2,589.00 |